Kobunai et al12 have reported that low sensitivity to 5-FU-based drugs is significantly correlated with a higher copy number and mRNA levels of the human DPD gene in 31 human tumour xenografts, suggesting that DPD is a potent predictive biomarker for 5-FU-based chemotherapy. This evidence concerns the gene DPYD and neoplasm.